GLP1R and type 2 diabetes mellitus: Since GLP-1 infusion may restore the incretin effect in patients with T2DM, the development of two incretin drug classes has been achieved—the GLP-1 receptor agonists and the dipeptidyl peptidase 4 (DPP-4) inhibitors (Figure 1).